Yes, Mounjaro can be used as a standalone treatment or alongside other diabetes medications such as metformin, sulfonylureas, or SGLT2 inhibitors.
FAQ
FAQ Description
Can Mounjaro assist with weight loss?
Yes, studies have indicated that Mounjaro can help people who are overweight or obese to lose a significant amount of weight, especially when combined with diet and exercise.
What should I do in the case of a Mounjaro (Tirzepatide) overdose?
If an overdose occurs, it is important to contact Poison Control for the latest recommendations. Supportive treatment should be initiated based on the patient’s clinical signs and symptoms. Considering the half-life of tirzepatide is approximately 5 days, a period of observation and treatment may be necessary.
How long does the effect of Mounjaro (Tirzepatide) last?
The half-life of tirzepatide is about 5 days, meaning it takes this time for the concentration of the drug to reduce by half in the body. If you stop taking Mounjaro, it should be gone from your body in about 30 days.
Is it necessary to take Mounjaro (Tirzepatide) with food?
No, it is not necessary to inject Mounjaro with food. Food does not affect how the medication is absorbed or its mechanism of action in the body. Therefore, you do not need to time the injection with meals. However, some find that taking medication with a meal helps them remember to take their doses.
How should I store Mounjaro (Tirzepatide)?
Mounjaro should be stored in the refrigerator until you are ready to inject a dose. It should be kept between 36°F to 46°F (2°C to 8°C).
What should I do if I forget to take my Mounjaro (Tirzepatide) dose?
If you miss a dose of Mounjaro, take the missed dose as soon as possible within 4 days (96 hours) after the missed dose. If it has been longer than 4 days, skip the missed dose and take your next dose on the regularly scheduled day.
Is Mounjaro (Tirzepatide) suitable for children?
The safety and efficacy of Mounjaro have not been established in pediatric patients. Currently, Mounjaro is not approved for use in patients younger than 18 years. Clinical trials are ongoing to evaluate its use in patients aged 10 to below 18 years with type 2 diabetes.
Who should avoid Mounjaro (Tirzepatide)?
Mounjaro should not be used by people with a personal or family history of medullary thyroid cancer or by those who have multiple endocrine neoplasia syndrome type 2.
Are there any precautions I need to take when using Mounjaro (Tirzepatide)?
As with all medications, you should follow the specific instructions provided by your healthcare provider. Be aware of the potential side effects, such as gastrointestinal symptoms, and contact your healthcare provider if you experience any adverse reactions.